Skip to content
10-Q

Quarterly Report

IGC Pharma, Inc. IGC

0001185185-24-000766

← back to feed
Filed
Aug 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Aug 5, 2024 75.64M sh
Long Term Debt Q1 2025 · Jun 30, 2024 $136K
Long Term Debt Q1 2025 · Mar 31, 2024 $137K
Short Term Debt Q1 2025 · Jun 30, 2024 $3K
Short Term Debt Q1 2025 · Mar 31, 2024 $3K
Cash And Equivalents Q1 2025 · Jun 30, 2024 $1.82M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $1.2M
Current Liabilities Q1 2025 · Jun 30, 2024 $2.49M
Current Liabilities Q1 2025 · Mar 31, 2024 $2.34M
Total Liabilities Q1 2025 · Jun 30, 2024 $2.71M
Total Liabilities Q1 2025 · Mar 31, 2024 $2.58M
Current Assets Q1 2025 · Jun 30, 2024 $4.41M
Current Assets Q1 2025 · Mar 31, 2024 $3.71M
Total Assets Q1 2025 · Jun 30, 2024 $10.59M
Total Assets Q1 2025 · Mar 31, 2024 $9.9M
Capex Q1 2025 · Jun 30, 2023 $20K
Operating Cash Flow Q1 2025 · Jun 30, 2023 −$1.47M
Stockholders Equity Q1 2025 · Jun 30, 2023 $13.2M
Stockholders Equity Q1 2025 · Mar 31, 2023 $14.91M
Sga Expense Q1 2025 · Jun 30, 2023 $1.65M
Rd Expense Q1 2025 · Jun 30, 2023 $747K
Net Income Q1 2025 · Jun 30, 2023 −$2.08M
Operating Income Q1 2025 · Jun 30, 2023 −$2.14M
Gross Profit Q1 2025 · Jun 30, 2023 $255K
Cost Of Revenue Q1 2025 · Jun 30, 2023 $300K
Revenue Q1 2025 · Jun 30, 2023 $555K